Predict your next investment

Envisia Therapeutics company logo
HEALTHCARE | Biotechnology
envisiatherapeutics.com

See what CB Insights has to offer

Stage

Series A - II | Alive

Total Raised

$46.1M

Valuation

$0000 

Last Raised

$16.5M | 6 yrs ago

About Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.

Envisia Therapeutics Headquarter Location

419 Davis Drive Suite 100

Morrisville, North Carolina, 27560,

United States

919-973-1440

Latest Envisia Therapeutics News

Global Ocular Drug Delivery Devices Market to 2027: Leading Players Include Novartis, Allergan, Graybug Vision and Envisia Therapeutics

Nov 12, 2021

News provided by Share this article Share this article DUBLIN, Nov. 12, 2021 /PRNewswire/ -- The "Ocular Drug Delivery Devices Market" report has been added to ResearchAndMarkets.com's offering. The global ocular drug delivery devices market is expected to grow at a CAGR of around 5.3% during 2021-2027. This report on global ocular drug delivery devices market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. The report presents a clear picture of the global ocular drug delivery devices market by segmenting the market based on technology, disease, formulation, end users, and region. Also, detailed profiles of companies operating in the ocular drug delivery devices market are provided in this report. We believe that this report will aid the professionals and industry stakeholders in making informed decision. Companies Mentioned Rising Incidence of Glaucoma and Macular Degeneration Increasing Number of Approvals Others

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Envisia Therapeutics Patents

Envisia Therapeutics has filed 3 patents.

The 3 most popular patent topics include:

  • Abandoned drugs
  • Blindness
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/5/2014

Dosage forms, Diseases of the eye and adnexa, Drug delivery devices, Prosthetics, Eye surgery

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/5/2014

00/00/0000

00/00/0000

Grant Date

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Dosage forms, Diseases of the eye and adnexa, Drug delivery devices, Prosthetics, Eye surgery

Subscribe to see more

Subscribe to see more

Status

Application

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.